---
title: "Tardive Dyskinesia Therapeutics Market: Growing at a CAGR of 9.1%"
datePublished: Mon Jul 17 2023 10:06:37 GMT+0000 (Coordinated Universal Time)
cuid: clk6pb313001o09mtdlo3bcsc
slug: tardive-dyskinesia-therapeutics-market-growing-at-a-cagr-of-91
cover: https://cdn.hashnode.com/res/hashnode/image/upload/v1689588361587/b1b8bc02-9cc2-4a58-85fa-41de393c3f34.png
tags: news, business, health-cjaeh844x02vvo3wtj5r2s75q, healthcare

---

**Tardive Dyskinesia Therapeutics Market Size, Share, By Drug (Deutetrabenazine, Valbenazine, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2023-2030**

Tardive dyskinesia (TD) is a movement disorder that can be caused by the long-term use of antipsychotic medications. The global tardive dyskinesia therapeutics market is growing at a CAGR of 9.1%, driven by the increasing prevalence of TD and the rising demand for effective treatments.

According to Recent Research Done By Fortune Business Insights, the global tardive dyskinesia therapeutics market size was valued at USD 2.33 billion in 2022 and is projected to grow from USD 2.77 billion in 2023 to USD 5.09 billion by 2030, exhibiting a CAGR of 9.1% during the forecast period.

ğ†ğğ­ ğŒğ¨ğ«ğ ğˆğ§ğ¬ğ¢ğ ğ¡ğ­ğ¬&gt;Â [https://www.fortunebusinessinsights.com/tardive-dyskinesia-therapeutics-market-107532](https://www.fortunebusinessinsights.com/tardive-dyskinesia-therapeutics-market-107532)

The most common treatments for TD include dopamine agonists, anticholinergics, and VMAT2 inhibitors. These medications work by increasing the levels of dopamine in the brain, blocking the effects of acetylcholine, or blocking the reuptake of dopamine.

The tardive dyskinesia therapeutics market is segmented by product type, distribution channel, and region. The product type segment is further segmented into dopamine agonists, anticholinergics, VMAT2 inhibitors, and others. The distribution channel segment is segmented into hospitals, clinics, and online pharmacies.

The key players in the tardive dyskinesia therapeutics market include Teva Pharmaceutical Industries Ltd, Neurocrine Biosciences, Inc, Sun Pharmaceutical Industries Ltd, SteriMax Inc., Lannett Co Inc, Sanis, and Allergan. These companies are investing in research and development to develop new and innovative treatments for TD.

The tardive dyskinesia therapeutics market is a rapidly growing market with significant potential. The market is expected to continue to grow in the coming years, driven by the factors mentioned above.

**Markt fÃ¼r SpÃ¤tdyskinesie-Therapeutika&gt;**Â [https://www.fortunebusinessinsights.com/de/markt-f-r-sp-tdyskinesie-therapeutika-107532](https://www.fortunebusinessinsights.com/de/markt-f-r-sp-tdyskinesie-therapeutika-107532)

**é…ç™ºæ€§ã‚¸ã‚¹ã‚­ãƒã‚¸ã‚¢æ²»ç™‚è–¬å¸‚å ´&gt;**Â [https://www.fortunebusinessinsights.com/jp/â€‹â€‹â€‹â€‹â€‹â€‹â€‹**/é…ç™ºæ€§ã‚¸ã‚¹ã‚­ãƒã‚¸ã‚¢æ²»ç™‚è–¬å¸‚å ´-107532**](https://www.fortunebusinessinsights.com/jp/â€‹â€‹â€‹â€‹â€‹â€‹â€‹/é…ç™ºæ€§ã‚¸ã‚¹ã‚­ãƒã‚¸ã‚¢æ²»ç™‚è–¬å¸‚å ´-107532)